{"bill":{"id":"119-hr-1476","congress":119,"type":"HR","number":1476,"title":"PLASMA Act","originChamber":"House","introducedDate":"2025-02-21","sponsors":[{"bioguideId":"H001067","fullName":"Rep. Hudson, Richard [R-NC-9]","party":"R","state":"NC","district":9}],"cosponsorsCount":5,"latestAction":{"actionDate":"2025-02-21","text":"Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned."},"policyArea":"Health","subjects":["Blood and blood diseases","Drug therapy","Health care costs and insurance","Manufacturing","Medicare","Prescription drugs"],"actions":[{"date":"2025-02-21","text":"Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.","type":"IntroReferral","chamber":"House floor actions","hasVote":false},{"date":"2025-02-21","text":"Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.","type":"IntroReferral","chamber":"House floor actions","hasVote":false},{"date":"2025-02-21","text":"Introduced in House","type":"IntroReferral","chamber":"Library of Congress","hasVote":false},{"date":"2025-02-21","text":"Introduced in House","type":"IntroReferral","chamber":"Library of Congress","hasVote":false}],"summary":"<p><strong>Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act</strong></p><p>This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.</p><p>Current law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold).&nbsp;</p><p>The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.</p>","updateDate":"2025-12-05T22:09:02Z"},"markets":[],"stateBills":[],"meta":{"sources":["congress.gov"],"latencyMs":474,"ts":"2026-04-15T04:56:17.222Z"},"nextActions":{"inspect":[],"related":[{"description":"Search related legislation","method":"GET","url":"/api/public/query-gov?q=PLASMA%20Act"}]}}